ViiV Healthcare and Halozyme partner to develop long-acting HIV therapies
ViiV Healthcare and Halozyme plan to start experiments with ENHANZE by year-end for the drug cabotegravir for HIV prevention.
Technology
Fujitsu to study Covid-19 treatments using supercomputer Fugaku
Fugaku will be used to discover small molecule inhibitory compounds and study molecular mechanism in...
Debiopharm and Ubix join forces to develop new anti-cancer modality
The companies are combining their proprietary technologies to develop Antibody Degraducer Conjugates.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science...
Gene writing: The future of genetic medicine?
Tessera Therapeutics’ new technology could write therapeutic messages into genomes, treating genetic diseases at their source.
Bacterial “cell factories”: an eco-friendly approach to chemical production
Researchers at the University of Warwick have designed a genetic switch that reroutes bacteria’s chemistry to produce chemicals.
Big data and AI are likely to lead emerging technology investments: Survey
With digital transformation gradually picking up pace, the pharmaceutical industry has witnessed an increase in investment in emerging technologies.
Impact of COVID-19 on emerging technology investment: Survey
The pharmaceutical industry made several adjustments in the emerging technology investment strategies following the COVID-19 pandemic.
Strong leadership dominates as key factor for digital transformation across geographies
The pharmaceutical industry believes that the top management of a company plays a crucial role in digital transformation.
Strong leadership continues to remain primary factor for digital transformation: Survey
The COVID-19 pandemic triggered new challenges for the pharmaceutical industry and forced them to revise their digitalisation strategies.
